1. Home
  2. QTTB vs WNW Comparison

QTTB vs WNW Comparison

Compare QTTB & WNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QTTB
  • WNW
  • Stock Information
  • Founded
  • QTTB 2015
  • WNW 2015
  • Country
  • QTTB United States
  • WNW China
  • Employees
  • QTTB N/A
  • WNW N/A
  • Industry
  • QTTB Biotechnology: Pharmaceutical Preparations
  • WNW Catalog/Specialty Distribution
  • Sector
  • QTTB Health Care
  • WNW Consumer Discretionary
  • Exchange
  • QTTB Nasdaq
  • WNW Nasdaq
  • Market Cap
  • QTTB 23.3M
  • WNW 26.6M
  • IPO Year
  • QTTB N/A
  • WNW 2020
  • Fundamental
  • Price
  • QTTB $2.27
  • WNW $1.58
  • Analyst Decision
  • QTTB Hold
  • WNW
  • Analyst Count
  • QTTB 7
  • WNW 0
  • Target Price
  • QTTB $12.17
  • WNW N/A
  • AVG Volume (30 Days)
  • QTTB 214.3K
  • WNW 15.5K
  • Earning Date
  • QTTB 11-07-2025
  • WNW 12-04-2025
  • Dividend Yield
  • QTTB N/A
  • WNW N/A
  • EPS Growth
  • QTTB N/A
  • WNW N/A
  • EPS
  • QTTB N/A
  • WNW 0.26
  • Revenue
  • QTTB N/A
  • WNW $2,550,178.00
  • Revenue This Year
  • QTTB N/A
  • WNW N/A
  • Revenue Next Year
  • QTTB N/A
  • WNW N/A
  • P/E Ratio
  • QTTB N/A
  • WNW $5.95
  • Revenue Growth
  • QTTB N/A
  • WNW N/A
  • 52 Week Low
  • QTTB $1.35
  • WNW $0.95
  • 52 Week High
  • QTTB $51.26
  • WNW $70.00
  • Technical
  • Relative Strength Index (RSI)
  • QTTB 40.57
  • WNW 37.83
  • Support Level
  • QTTB $2.50
  • WNW $1.45
  • Resistance Level
  • QTTB $2.61
  • WNW $1.77
  • Average True Range (ATR)
  • QTTB 0.31
  • WNW 0.14
  • MACD
  • QTTB -0.12
  • WNW -0.02
  • Stochastic Oscillator
  • QTTB 8.28
  • WNW 26.50

About QTTB Q32 Bio Inc. Common Stock

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

About WNW Meiwu Technology Company Limited

Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.

Share on Social Networks: